Does Dr. WAEL ABDELGHANI have financial conflicts of interest?

Dr. WAEL ABDELGHANI (M.D.) has received a total of $1,047 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $1,047 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. WAEL ABDELGHANI?

According to CMS Open Payments data, Dr. WAEL ABDELGHANI received funding from REGENERON HEALTHCARE SOLUTIONS ($345), NOVARTIS PHARMACEUTICALS CORPORATION ($126), and GENENTECH USA ($120).

Does Dr. WAEL ABDELGHANI receive research grants or speaking fees?

Dr. WAEL ABDELGHANI has received $1,047 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. WAEL ABDELGHANI

M.D.Real-Time Hydrated

Specialty: Ophthalmology

Practice Location: THE WOODLANDS, TX 77380

NPI Number: 1508837915

LIFETIME INDUSTRY VALUE

$1,047

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. ABDELGHANI is a verified Ophthalmology practitioner based in THE WOODLANDS, TX.

Between 2021 and 2025, Dr. ABDELGHANI had an overall industry promotional and research financial footprint of $1,047 as recorded in the federal CMS Open Payments database.

$1,047 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ABDELGHANI's primary funding source is REGENERON HEALTHCARE SOLUTIONS, which accounts for $345 (representing 33% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

REGENERON HEALTHCARE SOLUTIONS

Rank 1

$345

33%

NOVARTIS PHARMACEUTICALS CORPORATION

Rank 2

$126

12%

GENENTECH USA

Rank 3

$120

11.5%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.